# ARS Pharmaceuticals share price today (ARS Pharmaceuticals, Inc., SPRY)

> ARS Pharmaceuticals, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. SPRY · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/spry

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $3.05 (−65.5% in a year)
- Revenue (Jun 2026): $33.7 M (+114.2% on a year ago)
- Profit (Jun 2026), incl. one-off: −$62.3 M (one-off item, see below)
- Operating margin: −182.6% (+120.3 points on a year ago)

The main question: the share price moved −65.5% in a year while yearly earnings per share moved −2,275.0%. The difference came from the market paying a higher multiple. ## What is the ARS Pharmaceuticals share price today? ARS Pharmaceuticals, Inc.'s share price was $3.05 at the close on 4 November 2026. That is 58.1% below its average price over the last 200 trading days. In the last 52 weeks it traded between $3 and $13, and at that close it was at the low of that range. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 20 weeks running. Over the last 1 year the share price moved −83% while the S&P 500 moved +18%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 18 June 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does ARS Pharmaceuticals pay? ARS Pharmaceuticals, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is ARS Pharmaceuticals on? ARS Pharmaceuticals is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is ARS Pharmaceuticals profitable? ARS Pharmaceuticals, Inc. posted a net loss of $62.3 M in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $171 M. That loss is 185.2% of the quarter's revenue. The same quarter a year earlier lost $44.9 M. 11 of the last 12 reported quarters were loss-making. For the full year, FY25 profit was −$171 M (−2,241.8% on the year before). Read this profit with care: at −$62.3 M it is bigger than the quarter's whole revenue of $33.7 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −182.6% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does ARS Pharmaceuticals make, and is it growing? ARS Pharmaceuticals, Inc. reported $33.7 M of revenue in the Jun 2026 quarter, +114.2% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 4 years it has grown 97.8% a year on average. The last full year, FY25, came in at $84.3 M. The last four reported quarters add to $117 M. FY25 revenue was $84.3 M, −5.5% on the year before. Recent pace: the last four quarters grew +425.7% on average, against 97.8% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +4.1%, against +1,175.2% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does ARS Pharmaceuticals keep? ARS Pharmaceuticals, Inc.'s operating margin was −182.6% in the Jun 2026 quarter, 120.3 percentage points higher than the same quarter a year ago. Across 5 years it has been between −2,25,066.7% and −3.5%. The latest quarter is within that range. Why the margin moved: operating margin changed +120.3 percentage points on the year while gross margin changed +5.3 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is ARS Pharmaceuticals' profit turning into cash? ARS Pharmaceuticals, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $171 M of cash, against −$171 M of profit. After $339 K of spending on assets, free cash was −$171 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does ARS Pharmaceuticals' cash go? ARS Pharmaceuticals, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1.1 M on assets over the last 3 years. Averaged over those years that is 0.4% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $1.1 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is ARS Pharmaceuticals' P/E ratio, and how does it compare with its own history? ARS Pharmaceuticals, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values ARS Pharmaceuticals, Inc. at 3.6× its FY25 revenue of $84.3 M. The P/E comes back here once profit turns positive. Why the multiple is where it is: over the past year earnings per share moved −2,275.0% while the price moved −65.5%. The price did better than earnings, which pushed the multiple up within its own range. ## Is the ARS Pharmaceuticals business getting better or worse? ARS Pharmaceuticals, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 9 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does ARS Pharmaceuticals earn on its capital? ARS Pharmaceuticals, Inc. earned a ROE of −150% in FY25. Its return on capital used (ROIC) is left out: on sales this small it reads −8,135%, a number that says nothing useful about the business. It comes from a −203.3% net margin and 0.26× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −203.3% net margin × 0.26× asset turnover × 2.87× leverage (assets divided by equity) ≈ −151.7% on equity. The margin does its share; borrowing is a big part of it. ## Does ARS Pharmaceuticals have too much debt? ARS Pharmaceuticals, Inc. has total debt of $172 M against shareholder equity of $12.5 M as of Jun 2026, so its debt is 13.72× its equity. Year by year, that ratio went from 0.20 in FY21 to 1.47 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the ARS Pharmaceuticals shareholding pattern? 41.3% of ARS Pharmaceuticals, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 13.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is ARS Pharmaceuticals from balance-sheet trouble? For ARS Pharmaceuticals, Inc., the Z-score is −1.36. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −1.36 is inside the danger zone, so the balance sheet is a real risk. ## How does ARS Pharmaceuticals rank in its industry? There is no score against its industry: ARS Pharmaceuticals, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is ARS Pharmaceuticals compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to ARS Pharmaceuticals in size? ARS Pharmaceuticals is the 171st largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Agenus Inc., Enanta Pharmaceuticals, Inc. and Arcturus Therapeutics Holdings Inc. Just below it: Century Therapeutics, Inc., vTv Therapeutics Inc. and Ocugen, Inc. ### Biotechnology companies close in size

1. [Agenus Inc.](https://www.sectoralpha.in/us/stocks/agen) $314 million
2. [Enanta Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/enta) $310 million
3. [Arcturus Therapeutics Holdings Inc.](https://www.sectoralpha.in/us/stocks/arct) $309 million
4. ARS Pharmaceuticals, Inc. $303 million
5. [Century Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/ipsc) $302 million
6. [vTv Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/vtvt) $299 million
7. [Ocugen, Inc.](https://www.sectoralpha.in/us/stocks/ocgn) $297 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [First Western Financial, Inc.](https://www.sectoralpha.in/us/stocks/myfw) $304 million · Banks - Regional
2. [Alector, Inc.](https://www.sectoralpha.in/us/stocks/alec) $304 million · Biotechnology
3. ARS Pharmaceuticals, Inc. $303 million
4. [FVCBankcorp, Inc.](https://www.sectoralpha.in/us/stocks/fvcb) $303 million · Banks - Regional
5. [Canopy Growth Corporation](https://www.sectoralpha.in/us/stocks/cgc) $302 million · Drug Manufacturers - Specialty & Generic

## What else do people ask about ARS Pharmaceuticals? ### What were ARS Pharmaceuticals's latest quarterly results? ARS Pharmaceuticals, Inc. reported revenue of $33.7 M and a net loss of $62.3 M for the Jun 2026 quarter. Earnings per share were −$0.63. The operating margin was −182.6%, 120.3 percentage points higher than a year earlier (as of 4 November 2026). ### What is ARS Pharmaceuticals's market cap? ARS Pharmaceuticals, Inc.'s market capitalisation is $303 M at a stock price of $3.05. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is ARS Pharmaceuticals performing? ARS Pharmaceuticals, Inc.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 20 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will ARS Pharmaceuticals's stock price go up? This page does not forecast ARS Pharmaceuticals, Inc.'s stock price. What it shows instead: the stock price is $3.05. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Where is ARS Pharmaceuticals in its business cycle? ARS Pharmaceuticals, Inc.'s FY25 operating margin was −212.9%, against a 5-year range of −2,25,066.7% to −3.5%: the middle of its own range, neither a peak nor a low. The latest quarter was −182.6%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the ARS Pharmaceuticals story? The main question: the share price moved −65.5% in a year while yearly earnings per share moved −2,275.0%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is ARS Pharmaceuticals a stock worth studying right now? What the numbers show: ARS Pharmaceuticals, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.